Summary & Overview
HCPCS J0752: Oral Lenacapavir 300 mg for HIV PrEP
HCPCS Level II code J0752 represents oral lenacapavir 300 mg, authorized by the FDA exclusively for HIV pre-exposure prophylaxis (PrEP). As a pharmacy-dispensed antiretroviral prophylactic medication, this code matters nationally due to growing emphasis on biomedical HIV prevention, payer coverage decisions for newer PrEP agents, and implications for access and adherence programs.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for lenacapavir as PrEP, the typical sites of service where the drug is supplied, and the billing context for a specialty oral antiretroviral product. The publication outlines what to expect in payer coverage considerations, common billing modifiers in use, and practical service-line implications for outpatient pharmacies and ambulatory clinics.
This summary equips policy, billing, and clinical staff with a concise reference to the code’s purpose, the payer landscape addressed, and the types of benchmarks and policy updates covered in the full publication. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J0752 describes oral lenacapavir, 300 mg, an FDA-approved prescription product only for use as HIV pre-exposure prophylaxis (PrEP) and not for use as treatment for HIV. The service type is the pharmacy-dispensed prescription medication intended for HIV prevention.
Typical site of service is outpatient pharmacy or other ambulatory settings where oral antiretroviral prophylaxis is dispensed to patients for PrEP use.
Clinical & Coding Specifications
Clinical Context
A typical patient is an HIV-negative adult seeking HIV pre-exposure prophylaxis (PrEP) due to ongoing high-risk exposures (e.g., receptive or insertive anal or vaginal intercourse with partners of unknown or positive HIV status, condomless sex, or injection drug use). The patient presents to an outpatient sexual health clinic, primary care clinic, or specialty infectious disease practice. Clinical workflow: baseline evaluation includes HIV antigen/antibody testing, renal function (serum creatinine, eGFR), hepatitis B and C screening, pregnancy test if applicable, and STI screening. After confirming HIV-negative status and assessing suitability for PrEP, the clinician prescribes oral lenacapavir J0752 (300 mg) for PrEP per FDA indication. Medication dispensing is performed through the clinic pharmacy or external pharmacy; billing uses HCPCS Level II J0752. Follow-up visits occur at 1 month after initiation and then every 3 months for HIV testing, adherence counseling, STI screening, and monitoring for adverse effects. Typical site of service: outpatient clinic, community health center, or pharmacy-dispensed outpatient setting. Typical patient scenario: a 28-year-old cisgender man who has sex with men presenting after a partner disclosure of unknown HIV status; baseline labs are negative for HIV, renal function is normal, and clinician initiates oral lenacapavir J0752 for PrEP with a scheduled 1-month follow-up and quarterly monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|